William P Mayer, MD | |
3841 Piper Street, Suite T100, Anchorage, AK 99508 | |
(907) 561-3211 | |
(907) 562-7547 |
Full Name | William P Mayer |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 51 Years |
Location | 3841 Piper Street, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437177714 | NPI | - | NPPES |
060051651 | Other | AK | RAILROAD MEDICARE |
1010122 | Medicaid | AK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 1400 (Alaska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Providence Alaska Medical Center | Anchorage, AK | Hospital |
South Peninsula Hospital | Homer, AK | Hospital |
Alaska Regional Hospital | Anchorage, AK | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Alaska Heart Institute | 2668371469 | 57 |
Providence Health And Services Washington | 2163335746 | 25 |
South Peninsula Hospital Inc | 5395636930 | 38 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | Providence Health & Services Washington |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1467547265 PECOS PAC ID: 2163335746 Enrollment ID: O20031110000525 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | Alaska Heart Institute |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992744114 PECOS PAC ID: 2668371469 Enrollment ID: O20031231000146 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | Mat Su Valley Medical Center Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912950148 PECOS PAC ID: 5698686475 Enrollment ID: O20040123000583 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | Providence Health & Services Washington |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1952430902 PECOS PAC ID: 5799675120 Enrollment ID: O20040318000605 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | South Peninsula Hospital Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1679566269 PECOS PAC ID: 5395636930 Enrollment ID: O20040323000583 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Entity Name | Providence Health & Services Washington |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1013905660 PECOS PAC ID: 5799675120 Enrollment ID: O20041221000920 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
William P Mayer, MD Po Box 200149, Anchorage, AK 99520-0149 Ph: (907) 561-3211 | William P Mayer, MD 3841 Piper Street, Suite T100, Anchorage, AK 99508 Ph: (907) 561-3211 |
News Archive
Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.
Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.
Nitric oxide (NO) is best known as an air pollutant produced by vehicle emissions and power plants but for pregnant women it is a crucial compound required to avoid hypertension and pre-eclampsia.
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
› Verified 1 days ago
Andrea Caballero, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3220 Providence Dr Ste E3-080, Anchorage, AK 99508 Phone: 907-375-8785 Fax: 907-375-8788 | |
Daryl M. Mcclendon, M.D., P.C. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3851 Piper Street, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Dr. Loretta Leih-sheng Lee, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4001 Dale St, Suite 210, Anchorage, AK 99508 Phone: 907-929-5880 Fax: 907-929-5882 | |
Dr. Richard Merle Farleigh, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 4120 Laurel St, Suite 202, Anchorage, AK 99508 Phone: 907-561-4293 | |
Alexis Leandro Delgado, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4300 B St, Suite 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Geronimo Sahagun, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2841 Debarr Road, Suite 50, Anchorage, AK 99508 Phone: 907-276-2811 Fax: 907-276-2810 | |
Dr. Tram Phuong Chu, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3200 Providence Dr, Suite B111, Anchorage, AK 99508 Phone: 907-212-7890 Fax: 907-212-2374 |